Regression of atherosclerosis in female monkeys.
The objective of this study was to determine the structural and functional changes that occur in the artery wall in response to plasma lipid lowering and hormone replacement in surgically postmenopausal monkeys with established coronary artery atherosclerosis. Eighty-eight surgically postmenopausal cynomolgus monkeys were fed an atherogenic diet for 24 months and were then allocated into 4 groups: group 1 (n = 20), a baseline necropsy group; group 2 (n = 25), a lipid-lowering diet only; group 3 (n = 22), lipid lowering plus conjugated equine estrogen treatment equivalent to 0.625 mg/d for a woman; and group 4 (n = 21), lipid lowering plus conjugated equine estrogen and medroxyprogesterone acetate treatment (equivalent to 2.5 mg/d for a woman). Treatment was for 30 months. Histomorphometric analysis of perfusion-fixed coronary arteries revealed that plaque size did not change significantly in any of the groups compared with group 1 (P > .20). Plasma lipid lowering permitted coronary artery remodeling to occur (coronary artery and lumen size doubled compared with group 1) (P < .05); however, hormone therapy did not augment remodeling. Quantitative angiographic analysis of coronary artery reactivity revealed that lipid lowering improved dilator responses to acetylcholine by 22 +/- 4% (P = .01) but not to nitroglycerin (P = .23). Hormone replacement did not further affect vascular reactivity to the agonists tested (P > .4), but addition of medroxyprogesterone acetate diminished the beneficial effects of conjugated estrogens on coronary flow reserve (P = .03). In summary, the major arterial sequelae of lipid lowering in female monkeys were artery and lumen enlargement and improved reactivity of large epicardial coronary arteries. Addition of hormone replacement to the dietary modification did not further augment these improvements, except for the dilator capacity of the coronary microcirculation.
Williams
J K
JK
Comparative Medicine Clinical Research Center, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC 27157-1040, USA.
Anthony
M S
MS
Honoré
E K
EK
Herrington
D M
DM
Morgan
T M
TM
Register
T C
TC
Clarkson
T B
TB
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D001012:Aorta, Abdominal / Q000737:chemistry; D016632:Apolipoprotein A-I / Q000097:blood; D001161:Arteriosclerosis / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D002784:Cholesterol / Q000032:analysis; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D008076:Cholesterol, HDL / Q000097:blood; D003326:Coronary Circulation; D003331:Coronary Vessels / Q000473:pathology*; D004041:Dietary Fats / Q000008:administration & dosage; D004958:Estradiol / Q000097:blood; D015914:Estrogen Replacement Therapy; D005260:Female; D008055:Lipids / Q000097:blood*; D008252:Macaca fascicularis; D017258:Medroxyprogesterone Acetate / Q000097:blood / Q000627:therapeutic use; D010052:Ovariectomy; D017698:Postmenopause
D016632:Apolipoprotein A-I; D002791:Cholesterol, Dietary; D008076:Cholesterol, HDL; D004041:Dietary Fats; D008055:Lipids; D004958:Estradiol; D002784:Cholesterol; D017258:Medroxyprogesterone Acetate; D000109:Acetylcholine